Treatment, outcome, and prognostic factors in non-metastatic anal cancer: The French nationwide cohort study FFCD-ANABASE.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
06 2023
Historique:
received: 14 12 2022
revised: 02 02 2023
accepted: 11 02 2023
medline: 5 6 2023
pubmed: 23 2 2023
entrez: 22 2 2023
Statut: ppublish

Résumé

International guidelines regarding the treatment of squamous cell carcinoma of the anus (SCCA) recommend intensity-modulated radiotherapy (IMRT) combined with mitomycin-based chemotherapy (CT). The French FFCD-ANABASE cohort aimed at evaluating clinical practices, treatment, and outcomes of SCCA patients. This prospective multicentric observational cohort included all non-metastatic SCCA patients treated in 60 French centers from January 2015 to April 2020. Patients and treatment characteristics, colostomy-free survival (CFS), disease-free survival (DFS), overall survival (OS), and prognostic factors were analyzed. Among 1015 patients (male: 24.4 %; female: 75.6 %; median age: 65 years), 43.3 %presented with early-stage(T1-2, N0) and 56.7 % with locally advanced stage (T3-4 or N + ) tumors. IMRT was used for 815 patients (80.3 %) and a concurrent CT was administered in 781 patients, consisting of mitomycin-based CT for 80 %. The median follow-up was 35.5 months. DFS, CFS, and OS at 3 years were 84.3 %, 85.6 %, and 91.7 % respectively in the early-stage group compared to 64.4 %, 66.9 %, and 78.2 % in the locally-advanced group (p < 0.001). In multivariate analyses, male gender, locally-advanced stage, and ECOG PS ≥ 1 were associated with poorer DFS, CFS, and OS. IMRT was significantly associated with a better CFS in the whole cohort and almost reached significance in the locally-advanced group. Treatment of SCCA patients showed good respect for current guidelines. Significant differences in outcomes advocate for personalized strategies by either de-escalation for early-stage tumors or treatment intensification for locally-advanced tumors.

Identifiants

pubmed: 36813175
pii: S0167-8140(23)00080-4
doi: 10.1016/j.radonc.2023.109542
pii:
doi:

Substances chimiques

Fluorouracil U3P01618RT
Mitomycin 50SG953SK6

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

109542

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Véronique Vendrely (V)

Department of Radiation Oncology, CHU Bordeaux, Bordeaux, France; BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, University of Bordeaux, F-33000, Bordeaux, France. Electronic address: veronique.vendrely@chu-bordeaux.fr.

Claire Lemanski (C)

Department of Radiation Oncology, Montpellier Cancer Institute (ICM), Montpellier, France.

Pascal Pommier (P)

Radiotherapy, Léon Bérard Cancer Center, Lyon, France.

Karine LE Malicot (K)

Fédération Francophone de Cancérologie Digestive, university of Burgundy, Biostatistics, Dijon, France; EPICAD INSERM LNC-UMR 1231, University of Burgundy, Dijon, France.

Angélique Saint (A)

Department of Radiation Oncology, Antoine Lacassagne Cancer Center, Oncology, Nice, France.

Eleonor Rivin Del Campo (E)

Department of Radiation Oncology, Tenon University Hospital, APHP, Sorbonne University, Paris, France.

Pauline Regnault (P)

Radiotherapy, Tivoli Clinic, Bordeaux, France.

Nabil Baba-Hamed (N)

Oncology Department, Saint-Joseph Hospital group, Paris, France.

Philippe Ronchin (P)

Radiotherapy department, Azuréen Cancer Center, Mougins, France.

Gilles Crehange (G)

Radiotherapy department, Georges François Leclerc cancer center, Dijon, France.

David Tougeron (D)

Hepatology and Gastroenterology department, Poitiers University hospital, Poitiers, France.

Elodie Menager-Tabourel (E)

Medical Oncology, Departemental Hospital of Vendée, La Roche sur Yon, France.

Olivia Diaz (O)

Radiotherapy department, Daniel Hollard Institute, Grenoble, France.

Michael Hummelsberger (M)

Radiotherapy department, Radiotherapy and medical oncology center, Béziers, France.

Mathieu Minsat (M)

Radiation Oncology, Institut Curie, Saint Cloud, France.

Franck Drouet (F)

Mutualite Clinical Estuary, Saint Nazaire, France.

Anne Larrouy (A)

Médical Oncology, Cancer institute, North Paris, France.

Didier Peiffert (D)

Department of radiaton oncology, Lorraine cancer center, Vandoeuvre-Les-Nancy, France.

Astrid Lievre (A)

Gastroenterology Department, Rennes University Hospital, Rennes 1 University, Inserm U1242 COSS (Chemistry Oncogenesis Stress Signaling, Rennes, France.

Xavier Zasadny (X)

Oncology radiotherapy department, Limoges polyclinic François Chenieux, Limoges, France.

Vincent Hautefeuille (V)

Medical Oncology, CHU Amiens, Amiens, France.

Françoise Mornex (F)

Université Claude Bernard Lyon1, 69008 LYON, France.

Côme Lepage (C)

Department of hepato-gastroenterology, University hospital of Dijon, Dijon, France.

Laurent Quero (L)

INSERM U1160, Université Paris Cité, Paris, France; Radiotherapy Saint Louis Hospital, APHP, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH